TransMedics Group Affirms FY2026 Sales Guidance of $727.000M-$757.000M vs $737.825M Est

Benzinga Newsdesk www.benzinga.com Negative 73.8%

Neg 73.8% Neu 0% Pos 0%

TransMedics Group (NASDAQ:TMDX) affirms FY2026 sales outlook from $727.000 million-$757.000 million to $727.000 million-$757.000 million vs $737.825 million estimate.